The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
Veteran broadcaster Jane King from the NASDAQ MarketSite in Times Square interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
On November 16th, Dr. Jonathan Javitt joined Steve Darling from Proactive to discuss groundbreaking developments in the treatment of suicidal ideation and depression.
World Bipolar day is celebrated on March 30, the birthday of Dutch artist Vincent Van Gogh who died by suicide at 37 and was posthumously diagnosed as probably having a bipolar disorder. Bipolar disorder is a brain disorder that causes changes in a person’s mood, energy and ability to function.
NRx Pharmaceuticals, Inc. today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.
NRx Pharmaceuticals, Inc. today announced it has initiated a Phase 3 registrational trial targeting suicidal bipolar depression with suicidality and has signed the first clinical site contract.
See our Chief Scientist, Dr. Jonathan C. Javitt, provide a comprehensive description on why we are committed to solve for a very high unmet need in bipolar depression with suicidality.
NRx Pharmaceuticals enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality.
